BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583 [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kharouba M, El-Kamel A, Mehanna R, Thabet E, Heikal L. Pitavastatin-loaded bilosomes for oral treatment of hepatocellular carcinoma: a repurposing approach. Drug Deliv 2022;29:2925-44. [PMID: 36081339 DOI: 10.1080/10717544.2022.2120925] [Reference Citation Analysis]
2 Chen J, Zhao Y, Zhang F, Li J, Boland JA, Cheng NC, Liu K, Tiffen JC, Bertolino P, Bowen DG, Krueger A, Lisowski L, Alexander IE, Vadas MA, El-Omar E, Gamble JR, McCaughan GW. Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7. Cell Mol Life Sci 2022;79:443. [PMID: 35867177 DOI: 10.1007/s00018-022-04452-6] [Reference Citation Analysis]